Global Methane Mitigation Vaccine Market to Reach US$150 Million by 2031 at 13.6% CAGR, Led by ArkeaBio and Lucidome Bio

QYResearch's new report, Global Methane Mitigation Vaccine Market Outlook, In-Depth Analysis & Forecast to 2031, highlights that vaccines targeting ruminant methane emissions are transitioning from scientific vision to commercial reality. The market is projected to grow from US$ 62.5 million in 2024 to US$ 150 million by 2031, registering a 13.6% CAGR (2025-2031). Momentum has been reinforced by 2024-2025 breakthroughs, including venture investment into vaccine developers, philanthropic funding from climate foundations, and global buyer demand for scalable Scope 3 emissions reduction in beef and dairy.

Get Full PDF Sample Copy of Report: (Including Full TOC, List of Tables & Figures, Chart) https://www.qyresearch.com/sample/4812956

Leading Companies
ArkeaBio
Lucidome Bio
Pasture Biosciences
The Pirbright Institute - RVC Consortium
AgResearch / NZAGRC Program

Applications
Cattle
Sheep
Other Ruminants

Classification
Vaccines Targeting Methane-producing Archaea
Vaccines Modulating Immune Responses

Latest Data
Forecasted Market Size in 2031: US$ 150 million
CAGR (2025-2031): 13.6%
Forecast Units: USD million (value)
Coverage: Revenue and volume forecast, company share, competitive landscape, growth factors and trends
Regions: North America, Europe, Asia Pacific, South America, Middle East & Africa
Leading Companies in scope: Lucidome Bio, ArkeaBio
Segmentation by Type: Vaccines targeting methanogenic archaea; immune-response-modulating vaccines
Segmentation by Application: Cattle, Sheep, Other Ruminants

2024-2025 Updates and Achievements
ArkeaBio secured US$ 26.5 million in Series A funding led by Breakthrough Energy Ventures in 2024, accelerating its methane vaccine development with a stated aim to achieve market availability before 2030.

The Bezos Earth Fund awarded US$ 9.4 million in 2024 to an international research consortium led by The Pirbright Institute and the Royal Veterinary College, advancing early vaccine prototypes targeting a minimum 30% methane reduction.

Lucidome Bio launched in 2024 to commercialize 15 years of New Zealand's AgResearch/NZAGRC work, focusing on low-cost, pasture-suitable vaccines for multi-ruminant applications.

Economic analysis in 2025 proposed an Advance Market Commitment, with US$ 10.32 per dose incentives over 92 million doses, showing a projected benefit-cost ratio above 12:1 and providing a de-risked path to scale.

Scientific reviews in late 2024 confirmed antibody stability in the rumen and promising epitope targeting, but noted limited in-vivo data, underlining the early yet strategically critical nature of the field.

Product Snapshots
ArkeaBio - Methane-Reducing Vaccine for Cattle
Uses protein-antigen technology to stimulate salivary antibodies that neutralize methanogens in cattle rumen. Targets abatement cost below US$100 per ton CO2e. Backed by US$ 26.5 million in 2024, aiming for commercialization before 2030.

Lucidome Bio - Multi-ruminant Vaccine
Develops a vaccine inducing high-titer salivary antibodies stable in rumen environments. Designed for cattle, sheep, goats, buffalo, and deer. Emphasizes affordability and suitability for pasture-based systems, with commercialization roadmap launched in 2024.

Pasture Biosciences - mRNA Methane Vaccine
Pioneers mRNA-based vaccines to direct bovine immune responses toward methanogens. Conducting in vitro and in vivo trials since 2023, with the ambition to deliver cost-effective methane reductions across dairy and beef cattle.

Pirbright Institute - RVC Consortium - Cattle Methane Vaccine (Proof-of-concept)
Funded in 2024 to demonstrate antibody discovery, vaccination timing in calves, and proof-of-mechanism for methane reductions above 30%. Focused on foundational research for later commercialization.

AgResearch / NZAGRC Program - Salivary Antibody Vaccine
The original New Zealand program underpinning Lucidome Bio's product. Established stable antibodies against methanogens and identified conserved targets. Ongoing research sets efficacy thresholds at a minimum of 20% reduction in respiration chamber studies.

Downstream Customers
Arla Foods
Fonterra
Dairy Farmers of America
Nestlé
Danone
FrieslandCampina
Lactalis
Saputo
Glanbia
Yili Group
Mengniu Dairy
JBS
Tyson Foods
Marfrig
Cargill

Market Trend
Funding acceleration
From 2024 to 2025, funding shifted from small research grants to venture-scale investments. The Bezos Earth Fund and Breakthrough Energy Ventures positioned methane vaccines as a credible solution, while AgriZeroNZ and other farmer-backed groups secured support for pasture systems.

Vaccine economics
Analyses in 2025 project vaccines at production costs between US$ 1-4 per dose, with abatement below US$100 per ton CO2e. Advance Market Commitment proposals suggest strong economic returns, reinforcing feasibility for global rollout.

Pasture-based adoption
Unlike feed additives requiring daily dosing, vaccines fit seamlessly into existing herd health programs. Lucidome Bio and ArkeaBio emphasize calfhood vaccinations and pasture compatibility, critical for regions where intensive feeding is rare.

Scientific progress
Antibody stability and targeting have advanced significantly, but real-world methane reductions remain limited in published studies. Only a few research groups led the field in 2024, with more entrants emerging in 2025, gradually reducing technical risk.

Policy and buyer pull
Methane has become a central target in climate strategies. Dairy processors and meatpackers are under growing pressure from Scope 3 emissions reporting. Retailers are testing early pilots, and governments are embedding methane abatement into climate policies, creating early demand signals.

Request for Pre-Order Enquiry On This Report https://www.qyresearch.com/customize/4812956

Coexistence with other tools
Vaccines are viewed as complementary to feed additives, selective breeding, and manure management. The consensus is that a combined portfolio will deliver the largest reductions, aligning with global methane reduction pledges by 2030.

Communication and adoption risks
Misinformation has surfaced around methane reduction solutions, making transparency critical. Clear safety data and farmer engagement will be key to ensure vaccines are widely accepted and trusted when commercialized.

Chapter Outline:

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: key insights, key emerging trends, etc.
Chapter 3: Manufacturers competitive analysis, detailed analysis of the product manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 5 & 6: Sales, revenue of the product in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: The main points and conclusions of the report.

Contact Details
Tel: +1 626 2952 442 ; +41 765899438(Tel & Whatsapp); +86-1082945717
Email: john@qyresearch.com; global@qyresearch.com
Website: www.qyresearch.com

About us:
QY Research has established close partnerships with over 71,000 global leading players. With more than 20,000 industry experts worldwide, we maintain a strong global network to efficiently gather insights and raw data.

Our 36-step verification system ensures the reliability and quality of our data. With over 2 million reports, we have become the world's largest market report vendor. Our global database spans more than 2,000 sources and covers data from most countries, including import and export details.

We have partners in over 160 countries, providing comprehensive coverage of both sales and research networks. A 90% client return rate and long-term cooperation with key partners demonstrate the high level of service and quality QY Research delivers.

More than 30 IPOs and over 5,000 global media outlets and major corporations have used our data, solidifying QY Research as a global leader in data supply. We are committed to delivering services that exceed both client and societal expectations.

This release was published on openPR.